López-Álvarez, Marina
Heuker, Marjolein
Schoenmakers, Jorrit W. A.
van Dam, Gooitzen M.
McNamara, James O. II
van Dijl, Jan Maarten
van Oosten, Marleen
Funding for this research was provided by:
Horizon 2020 Framework Programme (713660 PRONKJEWAIL)
Article History
Received: 15 March 2020
Accepted: 25 September 2020
First Online: 5 November 2020
Competing interests
: J.O.M. is founder and CEO of Nuclease Probe Technologies Inc., and he holds patents on oligonucleotide-based nuclease-activatable probes for detection of bacterial nucleases. G.M.v.D. is CEO, founder and shareholder of AxelaRx/TRACER group, CSO AxelaRx Biosciences Inc. The other authors have no conflicts of interest to disclose.